Lightlake Therapeutics Inc. to Conduct Phase II Testing of New Bulimia Nervosa Treatment at King’s College London
05 Oktober 2011 - 2:50PM
Business Wire
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company” or
“Lightlake”), an early stage biopharmaceutical company using its
expertise of opioid antagonists to develop modern addiction
treatments, announced today that it will conduct Phase II trials at
King’s College London on an opioid antagonist-based nasal spray
treatment for Bulimia Nervosa.
Bulimia Nervosa is a condition affecting approximately 5 million
people in the US today, with only about 50% of these patients
finding successful treatment options. Lightlake—which is currently
performing Phase II trials in Helsinki, Finland on an opioid
antagonist-based nasal spray treatment for Binge Eating Disorder—is
confident that it can apply the same science to develop a solution
for Bulimia Nervosa. Moreover, in partnering with King’s College
London, which has an internationally recognized eating disorder
unit, to work on a trial that will involve the use of an opioid
antagonist nasal spray for the treatment of Bulimia Nervosa,
Lightlake believes that it has considerably strengthened the
Company’s already distinguished research and development team.
Dr. Roger Crystal, Chief Executive Officer of Lightlake,
commented, “We are very pleased to be working with King’s and to
have two remarkable people from the institution sponsoring our
Phase II trials. Professor Janet Treasure, head of the Eating
Disorders Unit at the South London and Maudsley NHS Trust and the
author of several well-regarded books on eating disorders, and
Professor Ulrike Schmidt, a consultant psychiatrist for the Eating
Disorders Service and a fellow of the Academy for Eating Disorders,
will be tremendous guides for our Phase II trials. It is an
absolute privilege to work with them and King’s in general, and we
look forward to coming to the institution early next year to test a
product that has the potential to improve the lives of so many
people.”
About Lightlake Therapeutics, Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical
company aiming to build a platform of biopharmaceutical solutions
to common addictions and related disorders. Currently, the Company
is focused on providing a safe, effective and simple treatment for
patients with Bulimia Nervosa as well as those who are obese or
overweight as a result of Binge Eating Disorder. Lightlake also
holds various patents that will allow it to widen its product
pipeline to address patients with addictions to opioid
painkillers, methadone, cocaine and amphetamine. The Company
anticipates launching a development program for each of these
purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no
obligation to update any of the forward-looking statements after
the date of this presentation to conform those statements to
reflect the occurrence of unanticipated events, except as required
by applicable law.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024